Dianthus Therapeutics (DNTH) News Today

Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase - Still a Buy?

Oppenheimer initiated coverage on Dianthus Therapeutics in a research report on Thursday. They issued an "outperform" rating and a $48.00 price target on the stock.

Point72 Asset Management L.P. decreased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 50.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 174,200 shares of the company's stock after selling 17

Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88

Fred Alger Management LLC cut its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 82.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,317 shares of the company's stock af

Point72 Asia Singapore Pte. Ltd. grew its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 281.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,504 shares of the c

Great Point Partners LLC lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 21.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 757,929 shares of the company'

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.2%

Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.5%

Bank of New York Mellon Corp boosted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 860.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 80,935 shares of the company's stock after purcha

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received a consensus rating of "Buy" from the ten research firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have issued a st

Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.3%

Atlas Venture Life Science Advisors LLC reduced its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 26.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 136,979 shares of the company's stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the target of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 4,060,000 shares, a growth of 10.9% from the July 31st total of 3,660,000 shares. Based on an average daily volume of 271,200 shares, the days-to-cover ratio is currently 15.0 days. Approximately 20.2% of the shares of the company are sold short.

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.7%

Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been assigned an average recommendation of "Buy" from the ten analysts that are presently covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation and two have

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totalling 3,660,000 shares, a growth of 9.6% from the July 15th total of 3,340,000 shares. Approximately 17.9% of the shares of the stock are sold short. Based on an average trading volume of 261,300 shares, the short-interest ratio is currently 14.0 days.

Dianthus Therapeutics (NASDAQ:DNTH) Trading 5.9% Higher

Vanguard Group Inc. increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 250.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 537,828 shares of the company's stock

HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday.

Wedbush reduced their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a research report on Friday.

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 9.6%

Janus Henderson Group PLC bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 375,044 shares of the company's stock, valued at approximately $11,251,000. Janus Hen

Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up to $28.09

Robert W. Baird started coverage on Dianthus Therapeutics in a research note on Friday. They set an "outperform" rating and a $58.00 target price for the company.

Atlas Venture Life Science Advisors LLC trimmed its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 21.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 186,979 shares of

Dianthus Therapeutics (NASDAQ:DNTH) Trading 4.8% Higher

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received a consensus rating of "Buy" from the eight analysts that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rati

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,970,000 shares, a decline of 5.3% from the May 31st total of 2,080,000 shares. Approximately 9.6% of the company's shares are sold short. Based on an average daily volume of 185,600 shares, the short-interest ratio is presently 10.6 days.